Sign in
Taking people in United StatesPhase 2

Roflumilast foam on the skin for hidradenitis suppurativa

Tests roflumilast foam applied to the skin in teens and adults with hidradenitis suppurativa.

Key facts

Who runs it
Harrison Dermatology
Where
Missouri City, United StatesSee the site
Trial code
Registry title
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Status
Recruiting
Phase
Phase 2
People taking part
10 people, planned
Started
10 Sept 2026
Expected to end
10 Dec 2028
Type of study
Interventional
Treatments tested
  • Roflumilast 0.3% topical foam
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12 years or older with mild to moderate hidradenitis suppurativa (HS), a long-lasting skin disease with painful lumps. Everyone uses roflumilast 0.3% foam on the skin once a day for 16 weeks.

Age
12 years or older
Sex
All sexes
Disease stage
HS diagnosed for at least 3 months, Hurley Stage I or II. At least 4 to ≤10 abscesses and inflamed lumps, in at least one body area. No draining tunnels under the skin.
Earlier treatment
No earlier roflumilast cream or foam. No oral roflumilast (Daxas® or Daliresp®) within 4 weeks before the start. Surgery in the treated area must be at least 3 months ago. People must agree not to use antibiotics, steroid injections into the lesions, bleach baths or certain antiseptic washes for HS during the study.

Main reasons for not taking part

  • Draining tunnels under the skin at screening or start
  • History of severe depression, suicidal thoughts or suicidal behaviour
  • Pregnant, planning pregnancy or breastfeeding
  • Cancer within 5 years, except some fully treated skin cancers or early cervical cancer
  • Severe kidney problems or moderate to severe liver problems (Child-Pugh B or C)

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Male or female subjects aged 12 years or older at time of consent (or assent)
  • Participants and/or legal guardians are legally competent to sign and give informed consent or assent (for adolescents)
  • Diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 3 months
  • Diagnosis of HS (Hurley Stage I or II) with a total abscess and inflammatory nodule (AN) count of at least 4 to ≤10, with no draining tunnels at screening and baseline visits, affecting at least one distinct anatomical region
  • Agreement to NOT use topical and systemic antibiotics and intralesional steroids for treatment of HS during the study
  • Agreement to NOT use a diluted bleach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the study
  • Subjects who have had surgery in the treatment area must be at least 3 months post-procedure (applies to deroofing/marsupialization or excision, not incision and drainage)
  • Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline/Day 1 and agree to use at least one highly effective or barrier method of contraception throughout the study; Females of non-childbearing potential must be premenarchal, postmenopausal (≥12 months spontaneous amenorrhea), or surgically sterile; -In good health as judged by the Investigator based on medical history, targeted physical examination, and vital signs. Subjects and parent(s)/legal guardian(s) must be reliable and capable of adhering to the protocol and visit schedule

Who cannot take part

  • Inability to discontinue prohibited medications or treatments before Baseline or during the study
  • Unwillingness to refrain from prolonged sun exposure or tanning beds/other artificial light-emitting devices for 4 weeks before Baseline and during the study
  • Use of oral roflumilast (Daxas® or Daliresp®) within 4 weeks before Baseline
  • Previous treatment with roflumilast cream or foam or current roflumilast use for another indication expected to continue during the study
  • Major surgery within 4 weeks before Baseline or planned during the study
  • History of chronic alcohol or drug abuse within 6 months before Screening
  • Medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
  • Skin conditions other than HS that could interfere with evaluation of study medication
  • Conditions in the treatment area that could confound efficacy measurements
  • Known allergy to excipients in roflumilast foam
  • History of severe depression, suicidal ideation, or suicidal behavior at Screening/Baseline
  • History of cancer within 5 years, except fully treated basal cell carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix
  • Known or suspected severe renal insufficiency or moderate to severe liver impairment (Child-Pugh B or C)
  • Presence of draining tunnels at Screening or Baseline
  • Pregnant, planning pregnancy during the study, or breastfeeding
  • Parent(s)/legal guardian(s) or subjects unable to communicate, read, or understand the local language, or otherwise unsuitable for participation in the Investigator's opinion
  • Family members of the clinical study site, study staff, sponsor, or family members of enrolled subjects living in the same household

Where in United States

  • Harrison Institute for Clinical Research at Harrison DermatologyMissouri City, United StatesContact: Harrison P Nguyen, MDTaking people

About the trial

What the trial wants to find out

This study investigates the efficacy of topical roflumilast foam in patients with HS.

The group in the trial

  • Roflumilast Foam 0.3Treatment being tested

    Experimental: Roflumilast 0.3% topical foam Roflumilast 0.3% topical foam to be applied QD to all active fields for the duration of the 16-week trial. Interventions: Drug: Roflumilast 0.3% topical foam

    Treatment: Roflumilast 0.3% topical foam

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Open-Label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Plain-language title
Roflumilast foam on the skin for hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 October 2026